日本語 中文
Contact
experiment in laboratory test tubes with pink liquid in

Life Sciences sustainability review

Sustainability is fully embedded in our business strategy, focusing on our customers sustainability expectations and needs, and steering innovation. For Life Sciences, sustainability is about impact, performance and value.

Agriculture

  • Sustainability trends continue to be driven by farm-level impacts, with Regenerative Agriculture becoming increasingly recognised as the future direction of travel for the sector.
  • Emerging regulation continues to reduce chemical inputs driving focus on efficiency, and use of biopesticides whilst improving yields.
  • Microplastic-free seed coatings are gaining traction as regulations tighten, but the shift also highlights the end-of-life impacts of older agricultural inputs. As legacy microplastics linger in soils, the industry is being pushed to consider the full life cycle of seed treatments and other agricultural inputs.

Our Agriculture business has responded by releasing a white paper on Regenerative Agriculture, highlighting the role of science-led innovation by companies like Croda, including biostimulants and microbial solutions, in improving soil health, biodiversity, and carbon capture. Our seed treatment business, Incotec, leads the market on microplastic-free seed treatment for crops and vegetables. We continued engaging with customers to explore opportunities to decarbonise ingredients and formulations, including identifying where reformulation can reduce active use, lowering costs and improving sustainability while maintaining performance.

Pharma

  • We have observed the continuation of clear and bold decarbonisation ambitions and strategies for many drug licence holders. These originator pharmaceutical companies are deepening their climate strategies, both in operations and across their value chains, signalling that decarbonisation is becoming increasingly core to their long-term business model.
  • Continued strong collaboration across the industry driving standards on environmental data and expectation of data sharing most critically as product carbon footprints. Continued strong collaboration across the industry driving minimum sustainability targets for supply chain. Priorities include lowering energy emissions, improving resource efficiency, understanding nature and water impacts, and increasing data sharing for key product carbon footprints.
  • Recognition that change in a highly regulated industry takes time. Focus to 2030 on utilisation of green electricity across supply chain and sharing of data. Acceleration 2030+ on deep decarbonisation and defossiliation of materials and chemicals to meet 2040+ Net Zero commitments.

In pharma, we continue to lead in sustainable vaccine adjuvants, scaling technologies to meet future vaccine demands whilst reducing impacts on biodiversity and improving security of supply. In 2025 our work on sustainable sourced squalene continued, launching cGMP grade material for customer use.